Page last updated: 2024-09-05

sorafenib and daunorubicin

sorafenib has been researched along with daunorubicin in 5 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(daunorubicin)
Trials
(daunorubicin)
Recent Studies (post-2010) (daunorubicin)
6,5207305,2518,2398861,310

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)daunorubicin (IC50)
72 kDa type IV collagenaseHomo sapiens (human)1.9
Multidrug resistance-associated protein 1 Homo sapiens (human)8
Histone deacetylase 1Homo sapiens (human)0.047
Histone deacetylase 8Homo sapiens (human)0.22
Histone deacetylase 6Homo sapiens (human)0.02

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Chen, Y; He, CM; Lin, DJ; Ruan, XX; Wang, LL; Xiao, RZ1
Geisberg, C; Pentassuglia, L; Sawyer, DB1
Chen, Y; He, CM; Lin, DJ; Ruan, XX; Wang, LL; Xiao, RZ; Xiong, MJ1
Aulitzky, W; Baldus, CD; Berdel, WE; Bornhäuser, M; Brandts, CH; Burchert, A; Dürk, H; Ehninger, G; Einsele, H; Frickhofen, N; Geer, T; Giagounidis, A; Görner, M; Hänel, M; Hase, J; Heits, F; Herbst, R; Hüttmann, A; Illmer, T; Junghanß, C; Kaiser, U; Kiani, A; Klut, IM; Krämer, A; Kramer, M; Krause, SW; Krug, U; Kullmer, J; Kunzmann, V; Link, H; Mackensen, A; Müller-Tidow, C; Neubauer, A; Noppeney, R; Parmentier, S; Reichle, A; Repp, R; Röllig, C; Schäfer-Eckart, K; Schaich, M; Schetelig, J; Serve, H; Thiede, C; von Bonin, M1

Reviews

2 review(s) available for sorafenib and daunorubicin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Cardiac side effects of anticancer treatments: new mechanistic insights.
    Current heart failure reports, 2012, Volume: 9, Issue:3

    Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Daunorubicin; Doxorubicin; Heart Failure; Humans; Indoles; Myocardial Contraction; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Trastuzumab

2012

Trials

1 trial(s) available for sorafenib and daunorubicin

ArticleYear
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:16

    Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Daunorubicin; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Germany; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Recurrence; Risk Factors; Sorafenib; Time Factors; Transplantation, Homologous; Treatment Outcome

2015

Other Studies

2 other study(ies) available for sorafenib and daunorubicin

ArticleYear
[Effect of sorafenib combined with daunorubicin on K562 cell line].
    Zhongguo shi yan xue ye xue za zhi, 2010, Volume: 18, Issue:3

    Topics: Apoptosis; Benzenesulfonates; Daunorubicin; Drug Synergism; Humans; K562 Cells; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib

2010
Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells.
    Oncology reports, 2013, Volume: 29, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butadienes; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; K562 Cells; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylation; Signal Transduction; Sorafenib; U937 Cells; Up-Regulation

2013